{"schema_version":"1.0","type":"article","title":"百濟神州一口氣押上 4 款 RAS 新藥","url":"https://drugnews.com.tw/articles/2026-08-22-revolution-medicines-beone-four-ras-programs.html","markdown_url":"https://drugnews.com.tw/articles/2026-08-22-revolution-medicines-beone-four-ras-programs.md","lang":"zh-Hant","date":"2026-08-22","publish_at":"2026-08-22T08:00:00+08:00","updated_at":"2026-08-22","category":"商業分析系列","topic":"商業分析系列","tags":["BeOne Medicines","百濟神州","Revolution Medicines","RAS(ON)","daraxonrasib","zoldonrasib","BGB-58067","BG-T187","BD 授權","腫瘤"],"summary":"百濟神州一次接進四款成熟度不同的 RAS(ON) 資產、兩條候選聯用路線與一項全球註冊三期。真正值得追的不是四藥相加，而是區域權利、開發分工與選擇權如何替雙方搶時間。","key_points":[],"facts":[],"sections":["01｜一次接進四種 RAS 戰法","02｜聯用才是這筆合作最有野心的地方","03｜亞洲權利看起來很大，邊界其實很細","04｜全案最大的伏筆：哪一款進全球三期？","05｜兩家公司各自買到什麼？","參考資料","免責聲明"],"references":[{"title":"[Revolution Medicines：雙方臨床開發與區域商業化合作公告（2026-08-10）]","source":"","date":"","url":"https://revmed.gcs-web.com/news-releases/news-release-details/revolution-medicines-and-beone-medicines-announce-clinical"},{"title":"[BeOne Medicines：雙方臨床開發與區域商業化合作公告（2026-08-10）]","source":"","date":"","url":"https://ir.beonemedicines.com/news/BeOne-Medicines-and-Revolution-Medicines-Announce-Clinical-Development-and-Regional-Commercialization-Collaboration/0a35a8d0-de94-4e43-a54c-c08af0e2e7ad"},{"title":"[SEC：BeOne Medicines 2026 年第一季 Form 10-Q 封面資料]","source":"","date":"","url":"https://www.sec.gov/Archives/edgar/data/1651308/000162828026030867/R1.htm"},{"title":"[BeOne Medicines：香港投資人繁中官網]","source":"","date":"","url":"https://hkexir.beonemedicines.com/zh-hant"},{"title":"[Revolution Medicines：臨床開發管線]","source":"","date":"","url":"https://www.revmed.com/pipeline/"},{"title":"[Revolution Medicines：FDA 受理 daraxonrasib NDA（2026-07-22）]","source":"","date":"","url":"https://ir.revmed.com/news-releases/news-release-details/revolution-medicines-new-drug-application-daraxonrasib-accepted/"},{"title":"[Revolution Medicines：RASolute 305 全球三期開始治療患者（2026-06-23）]","source":"","date":"","url":"https://ir.revmed.com/news-releases/news-release-details/revolution-medicines-begins-treating-patients-rasolute-305-phase/"},{"title":"[ClinicalTrials.gov：elironrasib／daraxonrasib Phase 1b/2，NCT06128551]","source":"","date":"","url":"https://clinicaltrials.gov/study/NCT06128551"},{"title":"[Revolution Medicines：RMC-5127 首位患者給藥（2026-01-29）]","source":"","date":"","url":"https://ir.revmed.com/news-releases/news-release-details/revolution-medicines-doses-first-patient-clinical-trial/"},{"title":"[ClinicalTrials.gov：RMC-5127 Phase 1/1b，NCT07349537]","source":"","date":"","url":"https://clinicaltrials.gov/study/NCT07349537"},{"title":"[BeOne Medicines：腫瘤管線]","source":"","date":"","url":"https://beonemedicines.com/science/pipeline/"},{"title":"[BeOne Medicines：全球臨床開發管線]","source":"","date":"","url":"https://beonemedicines.com/wp-content/uploads/2026/02/Clinical-Pipeline_2026-February.pdf"},{"title":"[ClinicalTrials.gov：BGB-58067，NCT06589596]","source":"","date":"","url":"https://clinicaltrials.gov/study/NCT06589596"},{"title":"[ClinicalTrials.gov：BG-T187，NCT06598800]","source":"","date":"","url":"https://clinicaltrials.gov/study/NCT06598800"},{"title":"查證截止日：2026 年 8 月 12 日。","source":"","date":"","url":""}],"images":[{"alt":"圖 1｜四款 RAS(ON) 資產涵蓋多重選擇性、G12D、G12C 與 G12V，成熟度從 NDA 審查到早期臨床","url":"https://drugnews.com.tw/assets/articles/revolution-medicines-beone-four-ras-programs/figure-01.png"},{"alt":"圖 2｜BGB-58067 與 BG-T187 可望搭配 daraxonrasib 或 zoldonrasib，但固定配對、癌別、劑量與時程尚未公布","url":"https://drugnews.com.tw/assets/articles/revolution-medicines-beone-four-ras-programs/figure-02.png"},{"alt":"圖 3｜合作涵蓋四款 RAS(ON) 資產、部分亞洲市場及一項全球註冊三期，但國家清單、財務條款與三期落點仍未完整披露","url":"https://drugnews.com.tw/assets/articles/revolution-medicines-beone-four-ras-programs/figure-03.png"}],"cover_image":"https://drugnews.com.tw/assets/articles/revolution-medicines-beone-four-ras-programs/cover-1400.webp","publisher":{"name":"Drugnews｜藥時事","url":"https://drugnews.com.tw/","profile":"https://drugnews.com.tw/brand-profile.json"},"citation":"Drugnews｜藥時事（2026-08-22）。百濟神州一口氣押上 4 款 RAS 新藥。https://drugnews.com.tw/articles/2026-08-22-revolution-medicines-beone-four-ras-programs.html","disclaimer":"本文僅供產業研究與知識分享，不構成投資、醫療、募資或個股建議。","translations":{"en":"2026-08-22-revolution-medicines-beone-four-ras-programs-en.html"},"relationship":"independent_editorial","disclosure_url":"https://drugnews.com.tw/policy/"}